Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 4/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | IL6ST | P40189 | 4/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949264 | 0.83 | PIK3CD (0.71) | PIK3CDARIL6STSTAT3IDH1 | |
| SCHEMBL18576421 | 0.83 | PIK3CD (0.71) | PIK3CDARIL6STSTAT3IDH1 | |
| SCHEMBL11949263 | 0.83 | PIK3CD (0.71) | PIK3CDARIL6STSTAT3IDH1 | |
| SCHEMBL23663783 | 0.80 | PIK3CD (0.43) | PIK3CDIL6STSTAT3GAA | |
| SCHEMBL20697286 | 0.80 | PIK3CD (0.53) | PIK3CDARP2RX7IL6STSTAT3 | |
| SCHEMBL2034701 | 0.75 | PIK3CD (0.40) | PIK3CDARP2RX7 | |
| SCHEMBL2033251 | 0.75 | PIK3CD (0.42) | PIK3CDIL6ST | |
| SCHEMBL2031183 | 0.74 | PIK3CD (0.42) | PIK3CDARP2RX7GAA | |
| SCHEMBL21582036 | 0.74 | EHMT2 (0.42) | PIK3CDIL6STIDH1 | |
| SCHEMBL21582034 | 0.74 | EHMT2 (0.42) | PIK3CDIL6STIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2485314-A1 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary cell | Mitsubishi Chemical Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8178246-B2 | Nonaqueous electrolyte solution, nonaqueous electrolyte secondary cell, and carbonate compounds | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-2339684-A2 | Nonaqueous electrolytic solution, nonaqueous electrolyte secondary cell, and carbonate compounds | Mitsubishi Chemical Corporation (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-10-08 | — | — | US | disclosed |
| CN-101218706-A | Nonaqueous electrolyte solution, nonaqueous electrolyte secondary battery, and carbonate compound | MITSUBISHI CHEM CORP (JP) | 2008-07-09 | — | — | CN | disclosed |
| EP-1890357-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CARBONATE COMPOUND | Mitsubishi Chemical Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | SLC9A1, NHERF1, CA2 | PIK3CD 2191/4885AR 413/4885P2RX7 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.